Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05524402 · ClinicalTrials.gov registry record · NA

Live Video Mind-body Treatment to Prevent Persistent Symptoms Following mTBI

A NA study of Anxiety and mTBI - Mild Traumatic Brain Injury, sponsored by Massachusetts General Hospital.

Completed
Registry status
NA
Development phase
50
Enrollment target
1
Study location

NCT05524402: Completed NA study of Anxiety and mTBI - Mild Traumatic Brain Injury, sponsored by Massachusetts General Hospital.

NCT05524402 is a NA study of Anxiety and mTBI - Mild Traumatic Brain Injury that has completed, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05524402, a NA study of Anxiety and mTBI - Mild Traumatic Brain Injury, has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

The investigator aims to conduct a pilot randomized controlled trial to test the feasibility of two symptom management programs for college-age individuals with recent concussions and anxiety, TOR-C 1 and TOR-C 2. The investigator will assess the feasibility of recruitment procedures (screening, eligibility, and enrollment) and data collection as well as the feasibility, credibility, and acceptability of the programs (adherence, retention, fidelity, and satisfaction), following prespecified benchmarks. Both programs will be delivered virtually (Zoom).

Primary Outcome

Assessed using the Credibility and Expectancy Questionnaire (CEQ) which asks the participant indicate how much they believe, right now, that the intervention they will receive will help manage their concussion and related worry. Possible scores on both the credibility and expectancy subscales range from 3 to 27 and have a midpoint score of 14. The number of participants that scored at or above 14 on the credibility and/or expectancy subscales are reported below.

Interventions

  • BEHAVIORAL TOR-C 1
  • BEHAVIORAL TOR-C 2

Study Locations (1)

Massachusetts

  • Massachusetts General Hospital - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2022-10-15
Est. Completion 2024-07-12
Phase NA
Massachusetts General Hospital

2,032 total trials

What the finished NCT05524402 record still lists

NCT05524402 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 440-participant average among 364 other Anxiety trials with a reported enrollment target (89% lower).

The record links to 2 conditions, with Anxiety appearing as the primary indexed condition, and to 2 interventions - of which TOR-C 1 is the first listed.

NCT05524402 reports a single indexed study location in Massachusetts.

Frequently Asked Questions

What is clinical trial NCT05524402 about?

NCT05524402 is a clinical study titled "Live Video Mind-body Treatment to Prevent Persistent Symptoms Following mTBI". The investigator aims to conduct a pilot randomized controlled trial to test the feasibility of two symptom management programs for college-age individuals with recent concussions and anxiety, TOR-C 1 and TOR-C 2. The investigator will assess the feasibility of recruitment procedures (screening, eli...

What is the current status of trial NCT05524402?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2022-10-15. Estimated completion is 2024-07-12.

What conditions does trial NCT05524402 study?

This clinical trial studies the following conditions: Anxiety, mTBI - Mild Traumatic Brain Injury.

What interventions are being tested in trial NCT05524402?

The interventions under investigation include: TOR-C 1 (BEHAVIORAL), TOR-C 2 (BEHAVIORAL).

Who is sponsoring clinical trial NCT05524402?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05524402 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Anxiety

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05524402's enrollment target sits among peer trials

50 246th of 364 higher than 110 of 364 other Anxiety trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Anxiety trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00200889 · 50 participants · Early Phase 1

    Mapping Auricular Vagus Nerve Circuitry

  • NCT00409435 · 50 participants · Phase 2

    A Study of Pyridostigmine in Postural Tachycardia Syndrome

  • NCT01202305 · 50 participants

    The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies

  • NCT01225913 · 50 participants · Phase 4

    Mechanism(s) of Airflow Limitation During Exacerbation of Asthma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05524402, the US trial registry maintained by the National Library of Medicine. NCT05524402 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.